Abstract

Trypanosoma cruzi parasites utilise de novo pyrimidine biosynthesis to produce DNA and survive within mammalian host cells. This pathway can be hijacked to assess the replication of intracellular parasites with the exogenous addition of a DNA specific probe. To identify suitable probe compounds for this application, a collection of pyrimidine nucleoside analogues was assessed for incorporation into T. cruzi intracellular amastigote DNA using image-based technology and script-based analysis. Associated mammalian cell toxicity of these compounds was also determined against both the parasite host cells (3T3 cells) and HEK293 cells. Incorporation of 5-ethynyl-2′-deoxyuridine (EdU) into parasite DNA was the most effective of the probes tested, with minimal growth inhibition observed following either two or four hours EdU exposure. EdU was subsequently utilised as a DNA probe, followed by visualisation with click chemistry to a fluorescent azide, to assess the impact of drugs and compounds with previously demonstrated activity against T. cruzi parasites, on parasite replication. The inhibitory profiles of these molecules highlight the benefit of this approach for identifying surviving parasites post-treatment in vitro and classifying compounds as either fast or slow-acting. F-ara-EdU resulted in <50% activity observed against T. cruzi amastigotes following 48 hours incubation, at 73 μM. Collectively, this supports the further development of pyrimidine nucleosides as chemical probes to investigate replication of the parasite T. cruzi.

Highlights

  • Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is considered one of the world’s 20 most neglected tropical diseases [1]

  • Chagas disease occurs within 21 countries in the Americas, causes over 10, 000 deaths per year and a further 25 million people are at risk of being infected

  • The cause of Chagas disease is Trypanosoma cruzi, a single celled protozoan parasite, which enters the bloodstream of a host by the bite of a “kissing bug”

Read more

Summary

Introduction

Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is considered one of the world’s 20 most neglected tropical diseases [1]. The nitro-heterocyclic drugs that are currently used to treat T. cruzi infection, nifurtimox (NFX) and benznidazole (BZ), have questionable efficacy in the chronic stage and associated toxicity often leads to cessation of treatment [3]. Lack of efficacy of the azole antifungal cytochrome P450 (CYP51) inhibitors, posaconazole and ravuconazole (E1224), in the treatment of chronic Chagas infection [5,6] has highlighted the need to understand more about the action of compounds on parasite replication. Improving efficacy and knowledge of the mode of action of new compounds effective against the parasite would support and accelerate the discovery of new drugs against Chagas disease

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call